Ansofaxine hydrochloride
CAS No. 916918-84-8
Ansofaxine hydrochloride( LY03005 | LPM570065 )
Catalog No. M20130 CAS No. 916918-84-8
Ansofaxine (LY03005; LPM570065) is a serotonin-norepinephrine-dopamine reuptake inhibitor (IC50s: 723 763 and 491 nM respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 113 | In Stock |
|
5MG | 164 | In Stock |
|
10MG | 278 | In Stock |
|
25MG | 509 | In Stock |
|
50MG | 731 | In Stock |
|
100MG | 1017 | In Stock |
|
500MG | 2034 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAnsofaxine hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionAnsofaxine (LY03005; LPM570065) is a serotonin-norepinephrine-dopamine reuptake inhibitor (IC50s: 723 763 and 491 nM respectively).
-
DescriptionAnsofaxine (LY03005; LPM570065) is a serotonin-norepinephrine-dopamine reuptake inhibitor (IC50s: 723 763 and 491 nM respectively).(In Vivo):Ansofaxine rapidly penetrates the rat striatum, converts into desvenlafaxine and exhibits larger total exposure compared with the administration of desvenlafaxine. Acute and chronic administration of oral suspension of ansofaxine increases the 5-HT, dopamine and norepinephrine levels more than the relative administration of desvenlafaxine. Unlike desvenlafaxine, acute administration of an intravenous ansofaxine solution does not induce the undesirable 90% decrease in extracellular 5-HT levels. The acute administration of ansofaxine shows a capped increase in extracellular 5-HT levels when combined with WAY-100635. Acute and chronic administration of ansofaxine reduces the immobility time more than the relative administration of desvenlafaxine.
-
In Vitro——
-
In VivoAnsofaxine rapidly penetrates the rat striatum, converts into desvenlafaxine and exhibits larger total exposure compared with the administration of desvenlafaxine. Acute and chronic administration of oral suspension of ansofaxine increases the 5-HT, dopamine and norepinephrine levels more than the relative administration of desvenlafaxine. Unlike desvenlafaxine, acute administration of an intravenous ansofaxine solution does not induce the undesirable 90% decrease in extracellular 5-HT levels. The acute administration of ansofaxine shows a capped increase in extracellular 5-HT levels when combined with WAY-100635. Acute and chronic administration of ansofaxine reduces the immobility time more than the relative administration of desvenlafaxine.
-
SynonymsLY03005 | LPM570065
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
Recptorserotonin reuptake| dopamine reuptake| norepinephrine reuptake
-
Research AreaNeurological Disease
-
IndicationMajor depressive disorder
Chemical Information
-
CAS Number916918-84-8
-
Formula Weight417.97
-
Molecular FormulaC24H32ClNO3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 30 mg/mL (71.77 mM)
-
SMILESCl.CN(C)CC(c1ccc(OC(=O)c2ccc(C)cc2)cc1)C1(O)CCCCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhang R et al. The effects of LPM570065 a novel triple reuptake inhibitor on extracellular serotonin dopamineand norepinephrine levels in rats. PLoS One. 2014 Mar 10;9(3):e91775.
molnova catalog
related products
-
Pectolinarin
Pectolinarin is a Cirsium isolate with anti-inflammatory activity.
-
Sumatriptan succinat...
Sumatriptan succinate is a serotonin1 (5-HT1) receptor agonist, which is effective in the acute treatment of migraine headache.
-
SB 737050A
SB 737050A is a potent, selective 5-HT6 receptor antagonist to prevent relapse intio addiction.